Challenges to smartphone applications for melanoma detection by Wang, Jordan V. et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Dermatology and Cutaneous
Biology Faculty Papers
Department of Dermatology and Cutaneous
Biology
2-2017
Challenges to smartphone applications for
melanoma detection
Jordan V. Wang
Thomas Jefferson University, jordan.wang@jefferson.edu
Lance W. Chapman
University of California, Irvine
Matthew S. Keller
University of California, Irvine
Let us know how access to this document benefits you
Follow this and additional works at: https://jdc.jefferson.edu/dcbfp
Part of the Dermatology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Dermatology and Cutaneous Biology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more
information, please contact: JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Wang, Jordan V.; Chapman, Lance W.; and Keller, Matthew S., "Challenges to smartphone
applications for melanoma detection" (2017). Department of Dermatology and Cutaneous Biology
Faculty Papers. Paper 69.
https://jdc.jefferson.edu/dcbfp/69
eScholarship provides open access, scholarly publishing
services to the University of California and delivers a dynamic
research platform to scholars worldwide.
Dermatology Online Journal
UC Davis
Title:
Challenges to smartphone applications for melanoma detection
Journal Issue:
Dermatology Online Journal, 23(2)
Author:
Wang, Jordan V, Department of Dermatology and Cutaneous Biology, Thomas Jefferson
University, Philadelphia, Pennsylvania
Chapman, Lance W, Department of Dermatology, University of California, Irvine
Keller, Matthew, Department of Dermatology and Cutaneous Biology, Thomas Jefferson
University, Philadelphia, Pennsylvania
Publication Date:
2016
Permalink:
http://escholarship.org/uc/item/4c37w7g2
Keywords:
smartphone, melanoma, dermatology, mobile apps, mobile health
Local Identifier:
doj_33976
Abstract:
This commentary addresses the emerging market forhealth-related smartphone applications.
Specific todermatology, there has been a significant increasenot only in applications that promote
skin cancerawareness and education but also in those meantfor detection. With evidence showing
that 365dermatology-related applications were available in2014--up from 230 in 2012--and that 1
in 5 patientsunder the age of 50 have used a smartphone tohelp diagnose a skin problem, there
is clearly a largesubset of patients participating in this growing trend.Therefore, we are obligated
to take a closer lookinto this phenomenon. Studies have shown thatapplications are inferior to in-
person consultationswith one study showing that 3 out of 4 applicationsincorrectly classified 30%
or more melanomas aslow-risk lesions. Although the FDA gained regulatoryoversight over mobile
health applications in 2012and recently released their statement in 2015, theirreach only extends
to cover a selected portion ofthese applications, leaving many unregulated asthey continue to be
marketed toward our patients.Dermatologists should be updated on our currentsituation in order
to properly counsel patients on therisks and benefits of these applications and whetherthey are
acceptable for use.
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Discussion
With the boom in health care technology and the rise 
in smartphone programming, it was only inevitable 
that both have merged to create a new market 
for health-related mobile applications. Specific to 
dermatology, there has been a significant increase 
not only in applications that promote skin cancer 
awareness and education but also in those meant 
for skin cancer detection. Nearly 230 dermatology-
related applications were available for download in 
2012 with that number rapidly expanding to 365 by 
2014 [1,2]. It appears that this number continues to 
grow. Of the available programs, most are free and 
predominately geared toward patients. Although no 
data exists for the exact number of users, it was found 
that one of every 5 patients under the age of 50 used 
a smartphone to help diagnose a skin problem [3]. 
Clearly, this demonstrates an emerging market.
Many applications can analyze a picture of a 
pigmented nevus and/or electronically transmit it 
to a dermatologist. Because of this, the first question 
that comes to mind is whether they can be trusted. 
Several studies have concluded that applications 
were inferior to in-person dermatologists and 
dermatopathologists in determining the likelihood 
of malignancy [4,5,6,7]. Results by Wolf et al. even 
showed that 3 out of 4 applications incorrectly 
classified 30% or more of melanomas as low-risk 
lesions [7].
Is this level of inaccuracy acceptable? And who 
determines what is ‘acceptable’? Until recently, 
no governing body regulated these applications. 
Without any requirements, there remained a 
gross lack of oversight for several years. In 2012, 
congress eventually approved the Food and Drug 
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Administration (FDA) Safety and Innovation Act, 
which gave the FDA authority to monitor a select 
subset of mobile medical applications. However, it 
was not until 2015 that the FDA issued a detailed 
statement [8]. Relevant to melanoma applications, 
those that analyze lesions using algorithms to 
provide risk assessment were now considered to be 
medical devices and subsequently fell under FDA 
oversight. However, those that transmit images 
to dermatologists were not required to follow 
regulations if intended to supplement a description 
for consultation. Although such applications tout 
the involvement of dermatologists, there is no 
requirement for the quality of their credentials. 
Therefore, many questions remain on how effective 
the FDA will ultimately prove to be and if it will further 
extend its reach.
There exists a high level of uncertainty with these 
applications. Results may be misinterpreted, which 
can place an unjust burden on users. When they 
are incorrectly reassured that a lesion is safe, they 
may miss a short window when early treatment of 
melanoma is significantly more responsive--thus 
delaying or even preventing care. The opposite case-
-when normal lesions are reported to be high-risk--
may at first be interpreted as beneficial since users 
would ideally seek professional care. However, the 
emotional and psychological toll may be unfair and 
excessive until they are able to see a dermatologist, 
which may take weeks to months.
The most important question that needs to be asked 
is: Are we doing ‘good’? At first glance, detecting 
possible melanomas may be seen as a victory, 
especially in areas that are rural, predominately 
uninsured, unsaturated with dermatologists, and/or 
prone to long patient wait times. However, relying 
solely on an application to screen for melanomas and 
alleviate any concerns that a lesion may be malignant 
is extremely flawed. Missing an early diagnosis for 
this severe disease could have drastic consequences 
in therapeutic options. Additionally, applications 
hold zero liability when they are incorrect, which--
unbeknownst to most users--is usually stated in their 
terms of use.
At this time, physicians should not recommend 
these applications, since the possibility for harm far 
outweighs any benefit. In diagnoses that are serious 
and urgent, there remains little room for error. 
As gatekeepers of the field, dermatologists must 
hold patient safety above all else. There is certainly 
the potential for applications to improve patient 
outcomes in the near future. However, we should 
advocate for their safe and effective implementation 
to allow for the most benefit but least amount of risk 
to our patients.
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